An official website of the United States government
Establish a consortium of genetics and genomics experts to develop and execute a large scale sequencing project to analyze the genomes of a large number of well characterized individuals including multi-ethnic subjects using next generation sequencing approaches; identify a broad range of AD and ADRD risk and protective gene variants in subjects with age-related dementias. These efforts should incorporate diverse sample sets (including racial/ethnic groups, the oldest old, and other well characterized individuals from epidemiological/observational studies) and include replication studies and data harmonization.
2020 PAR-14-070: Limited Competition: Renewal of, and Revisions to, the Alzheimer's Disease Genetics Consortium (U01) PAR-18-889: Limited Competition: Renewal of, and Revisions to, the Alzheimer's Disease Genetics Consortium (U01 Clinical Trial Not Allowed) PAR-17-214: Limited Competition: Analysis of Data from NIA's Alzheimer's Disease Sequencing Project Follow-Up Study (U01) PAR-19-288: Limited Competition: NIA Genome Center for Alzheimer's Disease (GCAD) (U54 Clinical Trial Not Allowed). (Reissue of RFA-AG-16-001) PAR-16-406: Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project (U01 Clinical Trial Not Allowed) PAR-19-234: Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project (U01 Clinical Trial Not Allowed) PAR-21-212: Limited Competition: AD Sequencing Project Follow Up Study RFA-AG-21-006: Alzheimer’s Disease Sequencing Project Functional Genomics Consortium (U01 Clinical Trial Not Allowed) RFA-AG-16-001: Genome Center for Alzheimer’s Disease (GCAD) (U54) RFA-AG-16-002: Alzheimer's Disease Sequencing Project (ADSP) Replication Phase Analysis Studies (U01) PAR-19-269: Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data RFA-AG-25-015: Coordination Center for the Alzheimer’s Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed) 6.B Achieved Establish a consortium of genetics and genomics experts to develop and execute a large scale sequencing project to analyze the genomes of a large number of well characterized individuals… DN 2012 AD Summit Blog: Working from home? Check out new genetics data for Alzheimer’s disease research! Workshop: Alzheimer’s Disease Genetics Global Symposium Research Highlight: Novel gene loci tied to risk of Alzheimer’s in African Americans Workshop: Alzheimer’s Disease Genetics Global Symposium: Pathway to Translation Drug Development - Novel Targets NIA Alzheimer’s Disease Genetics Portfolio Alzheimer’s Disease Genetics Consortium (ADGC) Alzheimer’s Disease Sequencing Project (ADSP) Recruitment and Retention for Alzheimer's Disease Diversity Cohorts in the Alzheimer’s Disease Sequencing Project (READD-ADSP) 2013
- Identification of new risk and protective alleles for late onset AD and related dementias that lead to the identification of at least one novel therapeutic approach, drug target or pathway for prevention.
Summary of Key Accomplishments
Through a series of targeted funding initiatives NIA established and continues to support the Alzheimer’s Disease Sequencing Project (ADSP). This program brings together 300 international investigators at 45 institutions with a goal to identify genes that increase or decrease the risk for Alzheimer’s across diverse populations. Increased support for genetics research has led to the discovery of more than 20 individual genes linked to increased risk of late-onset Alzheimer’s. The discovery of protective genetic factors such as a type of the KLOTHO gene that reduces risk of Alzheimer’s in individuals who carry the risk factor gene ApoE4 open new avenues for disease prevention.
The key accomplishments summary is current as of March 2022.